Brainscope today announced a number of new assignments to its executive roster, assigning 4 new picks to its c-suite.
The Bethesda, Ma.-based neurotech company picked up Dr. Leslie Prichep as chief scientific officer, Kerstin Schultz as president and COO, Angad Singh as chief technology officer, and promoted Laurie Silver to CFO.
“These additions to our leadership team will help us build upon the positive momentum that we have established over the last several years,” CEO Michael Singer said in a press release.
New prez and COO Schultz spent 4 years as vice president of global project management with Allergan, after spending 9 years in various positions with Baxter (NYSE:BAX). Previous to her time there, Schultz spent 2 years as a manager at A.T. Kearney.
Brainscope’s new CTO Singh came from an executive position at CardioMEMs, before it was acquired by St. Jude Medical (NYSE:STJ). Singh led CardioMEMs flagship heart failure sensor product from concept to commercialization, Brainscope said. Singh was also director for the development and commercialization of the EndoSure sensor.
Silver is transitioning to Brainscope from her position as director of mergers & acquisitions for the services group at Symantec, where she was responsible for leading the company’s $13 billion merger with Veritas.
Invuity snags Iridex’s Mackaness as CFO
Invuity (NSDQ:IVTY) said today it tapped former Iridex exec James Mackaness as the company’s new CFO. Mackaness was named Iridex’s COO in 2012, and served as CFO since 2008.
Read more
SEC OKs new CEO salary reporting rules
The SEC will now require that companies list their CEO’s total annual compensation as a ratio to their average worker’s pay, according to a new release from the agency.
Read more
Sanuwave picks Sundstrom as interim CFO
Sanuwave Health (OTC:SNWV) said last month its board of directors has promoted Lisa Sundstrom to interim CFO, effective July 31.
Read more
Staar Surgical takes a Holliday for R&D veep
Staar Surgical (NSDQ:STAA) said last week it has tapped ex-ReVision Optics Dr. Keith Holliday as its new veep of R&D, tasked with integrating the company’s proprietary Collamer material into its R&D continuum.
Read more
- Catalent appoints Carroll to board
- JumpTech taps Rutherford for biz dev veep
- Enteromedics adds to board
- Insulet appoints Hopfield to board
